Hemming Alan W, Reed Alan I, Langham Max R, Fujita Shiro, Howard Richard J
Department of Surgery, Center for Hepatobiliary Diseases, PO Box 100286, University of Florida, Gainesville, FL 32610-0286, USA.
Ann Surg. 2004 May;239(5):712-9; discussion 719-21. doi: 10.1097/01.sla.0000124387.87757.eb.
The objective of this paper is to review the results of combined resection of the liver and inferior vena cava for hepatic malignancy. The morbidity and mortality along with preliminary survival data are assessed in order to determine the utility of this aggressive approach to otherwise unresectable tumors.
Involvement of the inferior vena cava has traditionally been considered a contraindication to resection for advanced tumors of the liver because the surgical risks are high and the long-term prognosis is poor. Progress in liver surgery allows resection in some cases.
Twenty-two patients undergoing hepatic resection from 1997 to 2003, that also required resection and reconstruction of the inferior vena cava (IVC), were reviewed. The median age was 49 years (range 2 to 68 years). Resections were carried out for: hepatocellular carcinoma (n = 6), colorectal metastases (n = 6), cholangiocarcinoma (n = 5), gastrointestinal stromal tumor (n = 2), hepatoblastoma (n = 2), and squamous cell carcinoma in 1 patient. Liver resections performed included 13 right trisegmentectomies, 6 right lobectomies extended to include the caudate lobe, and 3 left trisegmentectomies. Complex ex vivo procedures were performed in 2 cases using venovenous bypass while the other 20 cases were performed using varying degrees of vascular isolation. In situ cold perfusion of the liver was used in 1 case. The IVC was reconstructed with ringed Gore-Tex tube graft (n = 14), primarily (n = 6), or with Gore-Tex patches (n = 2).
There were 2 perioperative deaths (9%). One cirrhotic patient died of liver failure 3 weeks post operatively and 1 patient with cholangiocarcinoma died of pulmonary hemorrhage secondary to a cavitating pulmonary infection after aspiration pneumonia 6 weeks after resection. Six patients had evidence of postoperative liver failure that resolved with supportive management and 2 patients required temporary dialysis. All vascular reconstructions were patent at last follow-up. With median follow-up of 26 months, 5 patients have died of recurrent malignancy at 44, 40, 32, 26, and 24 months, while an additional patient is alive with disease at 31 months. Actuarial 1-, 3-, and 5-year survivals were 85%, 60%, and 33%, respectively.
IVC involvement by hepatic malignancy does not necessarily preclude resection. Liver resection with reconstruction of the inferior vena cava can be performed in selected cases. The increased risk associated with the procedure appears to be balanced by the possible benefits, particularly when the lack of alternative curative approaches is considered.
本文旨在回顾肝恶性肿瘤联合肝切除及下腔静脉切除的结果。评估发病率、死亡率以及初步生存数据,以确定这种积极的手术方法对其他无法切除的肿瘤的实用性。
传统上,下腔静脉受累被认为是晚期肝癌切除的禁忌证,因为手术风险高且长期预后差。肝脏手术的进展使得在某些情况下可以进行切除。
回顾了1997年至2003年期间接受肝切除且同时需要切除和重建下腔静脉(IVC)的22例患者。中位年龄为49岁(范围2至68岁)。手术切除的疾病包括:肝细胞癌(n = 6)、结直肠癌转移瘤(n = 6)、胆管癌(n = 5)、胃肠道间质瘤(n = 2)、肝母细胞瘤(n = 2),另有1例为鳞状细胞癌。所进行的肝切除包括13例右三叶切除术、6例扩大至包括尾状叶的右叶切除术以及3例左三叶切除术。2例采用静脉-静脉旁路进行了复杂的体外手术,另外20例采用了不同程度的血管隔离。1例采用了肝脏原位冷灌注。下腔静脉采用带环的Gore-Tex人工血管重建(n = 14)、一期缝合(n = 6)或采用Gore-Tex补片(n = 2)。
围手术期死亡2例(9%)。1例肝硬化患者术后3周死于肝功能衰竭,1例胆管癌患者在切除术后6周因吸入性肺炎后继发空洞性肺部感染导致肺出血死亡。6例患者有术后肝功能衰竭的证据,经支持治疗后缓解,2例患者需要临时透析。所有血管重建在最后一次随访时均通畅。中位随访26个月,5例患者分别在44、40、32、26和24个月死于复发性恶性肿瘤,另有1例患者在31个月时带瘤存活。1年、3年和5年的精算生存率分别为85%、60%和33%。
肝恶性肿瘤累及下腔静脉不一定排除手术切除。在某些特定病例中可以进行肝切除并重建下腔静脉。该手术相关的风险增加似乎被可能的益处所平衡,特别是在考虑缺乏其他治愈性方法的情况下。